| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net revenues | $655.4M+8.3% | $605.2M+18.8% | $509.3M-5.3% | $537.8M+0.5% | $535.0M+8.2% | $494.4M+40.7% | $351.3M+41.6% | $248.1M+40.1% | $177.0M |
| Cost of revenues | $166.9M+21.6% | $137.2M+6.9% | $128.3M+11.7% | $114.9M-0.0% | $114.9M+7.9% | $106.5M+20.2% | $88.6M+10.7% | $80.0M+43.9% | $55.6M |
| Gross profit | $488.5M+4.4% | $468.0M+22.8% | $381.1M-9.9% | $423.0M+0.7% | $420.2M+8.3% | $387.9M+47.6% | $262.7M+56.4% | $168.0M+38.4% | $121.4M |
| Research, development and clinical studies | $224.5M+7.1% | $209.6M-6.0% | $223.1M+8.2% | $206.1M+2.4% | $201.3M+52.5% | $132.0M+67.1% | $79.0M+56.2% | $50.6M+32.7% | $38.1M |
| Sales and marketing | $240.1M+0.4% | $239.1M+5.4% | $226.8M+30.6% | $173.7M+26.7% | $137.1M+16.1% | $118.0M+22.1% | $96.7M+24.5% | $77.7M+22.3% | $63.5M |
| General and administrative | $177.7M-6.4% | $189.8M+15.7% | $164.1M+23.6% | $132.8M+5.3% | $126.1M+17.4% | $107.4M+22.2% | $87.9M+19.7% | $73.5M+24.3% | $59.1M |
| Total operating costs and expenses | $642.3M+0.6% | $638.5M+4.0% | $613.9M+19.8% | $512.5M+10.3% | $464.5M+29.9% | $357.5M+35.6% | $263.6M+30.7% | $201.7M+25.5% | $160.7M |
| Operating income (loss) | -$153.8M+9.8% | -$170.5M+26.8% | -$232.9M-160.1% | -$89.5M-101.9% | -$44.3M-245.8% | $30.4M+3426.1% | -$914K+97.3% | -$33.7M+14.4% | -$39.3M |
| Financial (expenses) income, net | $17.6M-55.4% | $39.3M-4.4% | $41.1M+435.8% | $7.7M+199.2% | -$7.7M+37.1% | -$12.3M | — | — | — |
| Total income (loss) before income taxes | -$136.3M-3.9% | -$131.2M+31.6% | -$191.7M-134.3% | -$81.8M-57.2% | -$52.1M-387.7% | $18.1M+305.1% | -$8.8M+80.8% | -$45.9M+5.3% | -$48.5M |
| Income tax | -$23K-100.1% | $37.5M+144.8% | $15.3M+43.2% | $10.7M+70.3% | $6.3M+467.9% | -$1.7M-7.0% | -$1.6M-109.0% | $17.6M+33.8% | $13.2M |
| Net income (loss) | -$136.2M+19.2% | -$168.6M+18.6% | -$207.0M-123.7% | -$92.5M-58.6% | -$58.4M-394.6% | $19.8M+374.0% | -$7.2M+88.6% | -$63.6M-3.1% | -$61.7M |
| Basic net income (loss) per ordinary share (in usd per share) | -$1220.00+21.8% | -$1560.00+20.0% | -$1950.00-121.6% | -$880.00-57.1% | -$560.00-380.0% | $200.00+385.7% | -$70.00+89.9% | -$690.00 | — |
| Diluted net income (loss) per ordinary share (in usd per share) | -$1220.00+21.8% | -$1560.00+20.0% | -$1950.00-121.6% | -$880.00-57.1% | -$560.00-411.1% | $180.00+357.1% | -$70.00+89.9% | -$690.00 | — |
| Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares) | $111471991000.00+3.4% | $107834368000.00+1.4% | $106391178000.00+1.7% | $104660476000.00+1.2% | $103433274000.00+2.5% | $100930866000.00+3.8% | $97237549000.00+5.9% | $91828043000.00 | — |
| Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares) | $111471991000.00+3.4% | $107834368000.00+1.4% | $106391178000.00+1.7% | $104660476000.00+1.2% | $103433274000.00-5.0% | $108877648000.00+12.0% | $97237549000.00+5.9% | $91828043000.00 | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Source: SEC EDGAR 10-K and 10-Q filings. Up to 10 years annual / 16 quarters shown.